NextFin news, On October 14, 2025, U.S.-based biotech firm Nabla Bio and Japan’s Takeda Pharmaceuticals announced a significant expansion of their collaboration focused on AI-driven protein design. Building on their initial partnership launched in 2022, the new multi-year agreement grants Takeda access to Nabla Bio’s proprietary AI platform, Joint Atomic Model (JAM), for designing de novo protein therapeutics. Nabla Bio will receive upfront and research payments in the double-digit millions, with eligibility for success-based payments potentially exceeding $1 billion. The collaboration centers on leveraging JAM to accelerate Takeda’s early-stage drug discovery programs, particularly targeting difficult-to-treat diseases with novel biologics such as multispecific antibodies and receptor decoys.
The JAM platform operates akin to a molecular auto-complete system, where it designs antibodies from scratch that bind specific disease targets with optimized properties. Nabla Bio’s CEO, Surge Biswas, highlighted JAM’s rapid feedback loop, enabling the generation and functional testing of up to a million antibody candidates within 2–3 weeks. This speed and precision mark a significant departure from traditional trial-and-error drug discovery methods. The platform’s success includes generating picomolar binders to challenging targets like G protein-coupled receptors (GPCRs) in zero-shot settings, demonstrating its robustness and versatility.
Takeda’s Chief Scientific Officer, Dr. Chris Arendt, emphasized the strategic importance of integrating cutting-edge AI technologies to accelerate drug development timelines and unlock new therapeutic spaces. This collaboration aligns with Takeda’s recent strategic shift away from cell therapy research, focusing instead on scalable, AI-enabled biologics development. The partnership also complements Takeda’s involvement in AI consortia with other pharmaceutical giants, such as Bristol Myers Squibb, to harness shared data for AI model training.
The deal reflects a broader industry trend where pharmaceutical companies increasingly invest in AI-driven platforms to reduce R&D costs and compress drug development cycles. Comparable collaborations include AstraZeneca’s $555 million partnership with Algen Biotechnologies and Eli Lilly’s $1.3 billion deal with Superlumnal Medicines, underscoring the competitive imperative to adopt AI technologies.
From a financial perspective, Nabla Bio’s ability to secure substantial upfront and milestone payments validates the commercial viability of AI-based protein design platforms. The potential for over $1 billion in success-based payments indicates confidence in the platform’s capacity to deliver clinically relevant candidates. This funding will likely accelerate Nabla’s internal R&D and expand its wet lab capabilities, reinforcing its position as a leading innovator in generative protein design.
Technologically, JAM’s integration of public protein data with proprietary experimental results enables a powerful foundation model approach, akin to breakthroughs recognized by the 2024 Nobel Prize in Chemistry for protein design. This synergy between AI and wet lab experimentation exemplifies the future of biologics discovery, where computational predictions are rapidly validated and optimized in the lab.
Looking ahead, the collaboration is poised to deliver first-in-human data for AI-designed molecules within one to two years, a timeline that could revolutionize early-stage drug development. The focus on multispecifics and challenging targets suggests potential breakthroughs in therapeutic areas with high unmet medical needs, such as oncology and immunology.
Strategically, Takeda’s pivot to AI-driven biologics and away from cell therapy reflects a pragmatic response to the evolving biotech landscape, prioritizing platforms with scalable manufacturing and faster clinical translation. For Nabla Bio, this partnership not only provides critical funding but also validates its platform’s applicability to large pharma pipelines, potentially opening doors to further collaborations.
In conclusion, the expanded Nabla Bio-Takeda partnership exemplifies the pharmaceutical industry’s accelerating embrace of AI to transform protein therapeutic discovery. By combining advanced AI models with rapid experimental validation, this collaboration promises to enhance drug discovery efficiency, reduce costs, and ultimately bring innovative therapies to patients faster. As AI platforms mature and integrate deeper into pharma R&D, similar multi-billion-dollar partnerships are expected to become the norm, reshaping the future of medicine development.
According to the American Chemical Society’s Chemical & Engineering News, this deal marks a pivotal moment in AI-driven biologics innovation, highlighting the growing trust and investment from major pharmaceutical players in generative AI technologies for drug discovery.
Explore more exclusive insights at nextfin.ai.
